Evidence map›Paper›PMID 39240791›Full record

ArticlePloS one2024

Multimodal smoking cessation treatment combining repetitive transcranial magnetic stimulation, cognitive behavioral therapy, and nicotine replacement in veterans with posttraumatic stress disorder: A feasibility randomized controlled trial protocol.

Jonathan R Young, Carri S Polick, Andrew M Michael, Moritz Dannhauer, Jeffrey T Galla, Mariah K Evans, Addison Troutman, Angela C Kirby, Michelle F Dennis, Claire W Papanikolas and 6 more

Abstract readClinical Trial Protocol
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Jonathan R YoungDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America.ORCID 0000-0001-5565-4894
Carri S PolickDurham VA Health Care System, Durham, North Carolina, United States of America.
Andrew M MichaelDuke Institute for Brain Sciences, Duke University, Durham, North Carolina, United States of America.
Moritz DannhauerDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America.
Jeffrey T GallaDepartment of Psychology and Neuroscience, Trinity College of Arts and Sciences, Duke University, Durham, North Carolina, United States of America.ORCID 0000-0001-6973-078X
Mariah K EvansDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America.
Addison TroutmanDurham VA Health Care System, Durham, North Carolina, United States of America.
Angela C KirbyDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America.
Michelle F DennisDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America.
Claire W PapanikolasDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America.
Zhi-De DengDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America.
Scott D MooreDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America.
Eric A DedertDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America.
Merideth A AddicottDepartment of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America.
Lawrence G AppelbaumDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America.
Jean C BeckhamDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America.

Funding

Non-invasive Neuromodulation Unit (NNU)ZIAMH002955 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2016 to 2025
$40.3M
BLRD VA IK6 BX003777CSRD VA I01 CX001757CSRD VA IK1 CX002187CSRD VA IK2 CX002610CSRD VA IK6 CX002767Intramural NIH HHS ZIA MH002955
6 · The paper itself

Abstract

Tobacco-related deaths remain the leading cause of preventable death in the United States. Veterans suffering from posttraumatic stress disorder (PTSD)-about 11% of those receiving care from the Department of Veterans Affairs (VA)-have triple the risk of developing tobacco use disorder (TUD). The most efficacious strategies being used at the VA for smoking cessation only result in a 23% abstinence rate, and veterans with PTSD only achieve a 4.5% abstinence rate. Therefore, there is a critical need to develop more effective treatments for smoking cessation. Recent studies suggest the insula is integrally involved in the neurocircuitry of TUD. Thus, we propose a feasibility phase II randomized controlled trial (RCT) to study a form of repetitive transcranial magnetic stimulation (rTMS) called intermittent theta burst stimulation (iTBS). iTBS has the advantage of allowing for a patterned form of stimulation delivery that we will administer at 90% of the subject's resting motor threshold (rMT) applied over a region in the right post-central gyrus most functionally connected to the right posterior insula. We hypothesize that by increasing functional connectivity between the right post-central gyrus and the right posterior insula, withdrawal symptoms and short-term smoking cessation outcomes will improve. Fifty eligible veterans with comorbid TUD and PTSD will be randomly assigned to active-iTBS + cognitive behavioral therapy (CBT) + nicotine replacement therapy (NRT) (n = 25) or sham-iTBS + CBT + NRT (n = 25). The primary outcome, feasibility, will be determined by achieving a recruitment of 50 participants and retention rate of 80%. The success of iTBS will be evaluated through self-reported nicotine use, cravings, withdrawal symptoms, and abstinence following quit date (confirmed by bioverification) along with evaluation for target engagement through neuroimaging changes, specifically connectivity differences between the insula and other regions of interest.

Indexed as

Cognitive Behavioral TherapySmoking CessationStress Disorders, Post-TraumaticTranscranial Magnetic StimulationVeteransAdultCombined Modality TherapyFeasibility StudiesFemaleHumansMaleMiddle AgedRandomized Controlled Trials as TopicTobacco Use Cessation DevicesTobacco Use Disorder

Identifiers

PMID39240791
PMCPMC11379281

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.